땅콩 알레르기 치료 시장 예측(-2034년) : 치료법별, 투여 경로별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Peanut Allergy Treatment Market is accounted for $734 million in 2026 and is expected to reach $1873 million by 2034 growing at a CAGR of 12.4% during the forecast period. Peanut allergy treatment involves various strategies to manage and alleviate allergic reactions triggered by the consumption of peanuts. Approaches include allergen avoidance, emergency interventions with epinephrine, and allergen immunotherapy, aimed at desensitizing the immune system. These treatments aim to enhance patient safety, minimize allergic responses, and improve the overall quality of life for individuals with peanut allergies.

According to the ITC trade map, in 2021, Argentina exported 634,080 metric ton of peanuts, followed by India with 563,268 metric ton in second place.

Market Dynamics:

Driver:

Increasing prevalence of peanut allergy

With a rising number of individuals diagnosed with peanut allergies globally, there is a growing need for effective treatment options. This trend propels research and development efforts towards innovative therapies, including allergen immunotherapy, emergency interventions, and preventive measures. Moreover, the expanding patient pool fosters market growth as pharmaceutical companies and healthcare providers address the demand for advanced and accessible treatments to manage and mitigate the risks associated with peanut allergies.

Restraint:

High cost of treatment

Expenses associated with allergen immunotherapy, emergency interventions, and ongoing medical management contribute to the financial burden on patients and healthcare systems. Limited insurance coverage for certain treatments further exacerbates the cost barrier. This high financial threshold may deter some individuals from seeking or continuing treatment, impacting overall patient adherence and outcomes.

Opportunity:

Rising awareness and diagnosis rates

Increased awareness among healthcare professionals and the general public about peanut allergies leads to early detection and diagnosis. As awareness grows, more individuals seek medical attention, creating a larger patient pool for treatment options. This trend not only improves patient outcomes by enabling timely interventions but also drives the demand for effective peanut allergy treatments. Pharmaceutical companies and healthcare providers can capitalize on this opportunity by developing innovative treatments, fostering education initiatives, and contributing to a more comprehensive understanding of peanut allergies in both medical communities and the public.

Threat:

Limited access to specialists and treatment centers

Limited access to specialists and treatment centers poses a significant threat to the peanut allergy treatment market. Patients facing peanut allergies may encounter challenges in accessing specialized healthcare professionals and designated treatment facilities. This limitation can hinder timely diagnosis, personalized treatment plans, and the administration of allergen immunotherapy. The scarcity of trained specialists may contribute to gaps in patient care, impacting the effectiveness of interventions.

Covid-19 Impact:

The COVID-19 pandemic has impacted the peanut allergy treatment market by causing disruptions in healthcare services, including allergy diagnostics and treatments. Lockdowns, restrictions, and shifts in healthcare priorities led to delays in patient care, diagnosis, and treatment initiation. Additionally, the pandemic affected clinical trials and research activities, influencing the overall landscape of peanut allergy treatment. As the situation stabilizes, the market is gradually recovering, with an increased emphasis on patient safety and innovative treatment approaches.

The Immunotherapies segment is expected to be the largest during the forecast period

The immunotherapies segment is anticipated to be the largest in the peanut allergy treatment market during the forecast period. This dominance is attributed to the increasing adoption of allergen immunotherapy, including subcutaneous and sublingual approaches, aimed at desensitizing the immune system to peanuts. With a focus on addressing the root cause of peanut allergies and reducing allergic reactions, immunotherapies emerge as a preferred treatment option, contributing to the segment's substantial market share growth.

The injectable segment is expected to have the highest CAGR during the forecast period

The injectable segment is projected to experience lucrative growth in the peanut allergy treatment market during the forecast period. This growth is driven by the increasing preference for injectable forms of treatment, particularly the use of epinephrine auto-injectors for emergency management of severe allergic reactions. With a heightened focus on rapid and efficient intervention during allergic emergencies, the injectable segment is poised for substantial growth, offering a convenient and effective solution for patients and caregivers.

Region with largest share:

North America is poised to dominate the peanut allergy treatment market due to advanced healthcare infrastructure, heightened awareness of peanut allergies, and a proactive regulatory environment. The region's focus on innovative therapies, including immunotherapies, and a higher prevalence of peanut allergies contribute to its market leadership. Additionally, collaborations between healthcare organizations and research institutions further drive advancements in peanut allergy treatment, positioning North America as a key hub for developments and market dominance.

Region with highest CAGR:

The European region foresees rapid growth in the peanut allergy treatment market due to the increasing prevalence of peanut allergies, a strong emphasis on healthcare research, and advancements in treatment options. Rising awareness among healthcare professionals and patients, coupled with supportive regulatory frameworks, propels the adoption of innovative peanut allergy therapies. As research and development efforts intensify, Europe emerges as a significant contributor to advancements in peanut allergy treatment, driving substantial market growth in the forecasted period.

Key players in the market

Some of the key players in Peanut Allergy Treatment Market include Aimmune Therapeutics, ALK-Abello A/S, Alladapt Immunotherapeutics, Inc, AnaptysBio, Inc., DBV Technologies SA, GlaxoSmithKline plc, HAL Allergy Group, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Prota Therapeutics, Regeneron Pharmaceuticals, Sanofi and Stallergenes Greer.

Key Developments:

In June 2023, Alladapt Immunotherapeutics, Inc. has unveiled topline results of Phase 1/2 Harmony study assessing effectiveness & safety of ADP101 for treating food allergies. Outcomes indicate dose-dependent, clinically significant responses, and a favorable safety profile in pediatric patients with single or multiple food allergies. These promising findings suggest ADP101's potential as a safe and effective treatment for children with common food allergies.

In May 2023, DBV Technologies has made an announcement that the results of its Phase 3 EPITOPE trial involving EPIT using Viaskin Peanut in children aged 1 to 3 years have been published in the New England Journal of Medicine. This publication underscores the potential of a new food allergy treatment option for this specific age group, offering hope for the management of food allergies in young children.

Treatment Types Covered:

• Epinephrine
• Antihistamines and Corticosteroids
• Immunotherapy
• Other Treatment Types

Route of Administrations Covered:

• Oral
• Injectable

End Users Covered:

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Homecare Settings

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Peanut Allergy Treatment Market, By Treatment Type

• 5.1 Introduction
• 5.2 Epinephrine
• 5.3 Antihistamines and Corticosteroids
• 5.4 Immunotherapy
• 5.5 Other Treatment Types

6 Global Peanut Allergy Treatment Market, By Route Of Administration

• 6.1 Introduction
• 6.2 Oral
• 6.3 Injectable

7 Global Peanut Allergy Treatment Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Clinics
• 7.5 Ambulatory Surgical Centers
• 7.6 Homecare Settings

8 Global Peanut Allergy Treatment Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Aimmune Therapeutics
• 10.2 ALK-Abello A/S
• 10.3 Alladapt Immunotherapeutics, Inc
• 10.4 AnaptysBio, Inc.
• 10.5 DBV Technologies SA
• 10.6 GlaxoSmithKline plc
• 10.7 HAL Allergy Group
• 10.8 Merck & Co., Inc.
• 10.9 Mylan N.V.
• 10.10 Novartis AG
• 10.11 Pfizer Inc.
• 10.12 Prota Therapeutics
• 10.13 Regeneron Pharmaceuticals
• 10.14 Sanofi
• 10.15 Stallergenes Greer